Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma
- 21 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Tumor Biology
- Vol. 34 (6), 3529-3536
- https://doi.org/10.1007/s13277-013-0931-8
Abstract
M30 and M65 are relatively new assays that detect different circulating forms of the epithelial cell structural protein cytokeratin 18. This study was conducted to investigate the serum levels of M30 and M65 in patients with metastatic pancreatic adenocarcinoma (MPA) and the relationship with tumor progression and known prognostic parameters. Twenty-six patients with MPA were investigated. Serum samples were obtained on first admission before treatment and follow-up. Both serum M30 and M65 levels were determined using enzyme-linked immunosorbent assay. The median age at diagnosis was 59 years, range 32–80 years; 14 patients were men. All patients had metastatic stage, and most (n = 21, 81 %) had hepatic metastasis. The baseline levels of both serum M30 and serum M65 were significantly higher in patients with MPA than those in the control group (p < 0.001, for both assays). Serum M65 level was only significantly higher in the patients with elevated serum LDH levels than in others with normal serum LDH levels (p = 0.03). For serum M30 levels, no correlation was found. The significant relationship was found between the serum levels of M30 and M65 (r s = 0. 926, n = 26, p < 0.001, Spearman’s correlation). The median survival for all patients was 31.7 ± 2.2 weeks (95 % CI = 27.31–36.08). Although only the serum LDH level was found to be a significant prognostic factor (p = 0.01), neither serum M30 nor serum M65 had significant effect on survival (p = 0.28 and p = 0.15, respectively). In conclusion, although both serum levels of M30 and M65 assays were found to be of diagnostic value, no predictive and prognostic values were determined in MPA patients.Keywords
This publication has 24 references indexed in Scilit:
- Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomasEuropean Journal of Cancer, 2010
- Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancerBritish Journal of Cancer, 2010
- Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patientsEuropean Journal of Surgical Oncology, 2009
- Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour responseBritish Journal of Cancer, 2009
- Circulating cell death products predict clinical outcome of colorectal cancer patientsBMC Cancer, 2009
- Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activityMolecular Cancer Therapeutics, 2008
- Optimisation of circulating biomarkers of cell death for routine clinical useAnnals of Oncology, 2008
- Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to ChemotherapyClinical Cancer Research, 2007
- Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot StudyCancer Investigation, 2006
- A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patientsScandinavian Journal of Clinical and Laboratory Investigation, 1995